0:00
/
0:00
Transcript

Bispecific antibodies (BsAbs), Antibody Discovery and Therapeutics

Luke McLaughlin, Biotech Digital Marketer, Business Developer and Life Science Content Creator

Bispecific antibodies (BsAbs) are a class of artificial proteins that are engineered to recognize two different antigens or epitopes. This capability allows them to simultaneously engage two different types of targets, such as cancer cells and immune cells, which can enhance the body's immune response against tumors or address complex diseases that require the modulation of multiple biological pathways. Bispecific antibodies represent a significant advancement in therapeutic antibody engineering and offer promising strategies for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

Discussion about this video